Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 96
Filtrar
1.
Chest ; 160(1): 351-357, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33667489

RESUMO

BACKGROUND: Patients with malignant pleural effusions (MPEs) experience breathlessness and poor survival. Breathlessness is associated with poor survival in other conditions. RESEARCH QUESTION: Is breathlessness, measured using a visual analog scale for dyspnea (VASD), associated with survival in patients with MPE? STUDY DESIGN AND METHODS: Individual patient data from five randomized controlled trials of 553 patients undergoing interventions for MPE were analyzed. VASD was recorded at baseline and daily after intervention. Patients were followed up until death or end of trial. Univariate and multivariable Cox regression were used to identify factors associated with survival. RESULTS: Baseline VASD was significantly associated with worse survival, with a hazard ratio of 1.10 (95% CI, 1.06-1.15) for a 10-mm increase in VASD. On multivariable regression, it remained a significant predictor of survival. Mean 7-day VASD and mean total VASD were also predictors of survival (mean 7-day VASD: hazard ratio [HR], 1.26 [95% CI, 1.19-1.34]; total VASD: HR, 1.25 [95% CI, 1.15-1.37]). Other predictors of survival were serum C-reactive protein level and tumor type. Previous treatment with chemotherapy, performance status, pleural fluid lactate dehydrogenase, serum albumin, hemoglobin, serum neutrophil:lymphocyte ratio, and size of effusion were associated with survival on univariate but not multivariable analysis. INTERPRETATION: Breathlessness, measured using VASD at baseline and postprocedure, is a predictor of survival in patients with MPE.


Assuntos
Dispneia/etiologia , Derrame Pleural Maligno/mortalidade , Ensaios Clínicos Controlados Aleatórios como Assunto , Dispneia/mortalidade , Dispneia/fisiopatologia , Saúde Global , Humanos , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/fisiopatologia , Taxa de Sobrevida/tendências
3.
Respirology ; 25(11): 1167-1173, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32249488

RESUMO

BACKGROUND AND OBJECTIVE: The advent of effective anti-cancer therapy has brought about uncertainty on the benefit of early definitive measures for newly diagnosed MPE from lung cancer. This study aims to investigate the outcomes of MPE in this setting. METHODS: Lung cancer patients with MPE at first presentation to a tertiary care hospital were followed up till death or censored from 2011 to 2018. Early MPE control measures included chemical pleurodesis or IPC before or shortly after oncological treatment. Predictors of time to MPE re-intervention were identified with Cox proportional hazard analyses. RESULTS: Of the 509 records screened, 233 subjects were eligible. One hundred and twenty-seven subjects received oral targeted therapy as first-line treatment and 34 (26.8%) underwent early definitive MPE control measures. Early MPE control measures in addition to targeted therapy, as compared to targeted therapy alone, significantly reduced the subsequent need of MPE re-intervention (23.5% vs 53.8%, P = 0.002). Similar benefits from MPE control measures were found in groups receiving systemic anti-cancer therapy or best supportive care (0% vs 52%, P = 0.003; 18% vs 56.7%, P = 0.024, respectively). In the group with targetable mutations, both early MPE control measures (HR: 0.25, 95% CI: 0.12-0.53, P < 0.001) and the use of targeted therapy (HR: 0.22, 95% CI: 0.10-0.46, P < 0.001) were independently associated with longer time to MPE re-interventions. CONCLUSION: Early MPE control measures in lung cancer has additional benefits on reducing the need and prolonging the time to MPE re-intervention, independent of anti-cancer therapies.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Pulmonares , Derrame Pleural Maligno , Pleurodese/métodos , Toracentese/métodos , Idoso , Feminino , Humanos , Estudos Longitudinais , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/patologia , Masculino , Terapia de Alvo Molecular/métodos , Avaliação de Resultados em Cuidados de Saúde , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/terapia , Retratamento/estatística & dados numéricos , Tempo para o Tratamento
4.
Pan Afr Med J ; 35: 3, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32117519

RESUMO

INTRODUCTION: The aim of this study is to compare the use of flutter valve drainage bag system as an alternative to conventional underwater seal drainage bottle in the management of non-massive malignant/paramalignant pleural effusion. METHODS: Forty-one patients with non-massive malignant and paramalignant pleural effusions were randomized into two groups. Group A (21patients) had their chest tubes connected to an underwater seal drainage bottle, while group B (20 patients) had their chest tubes connected to a flutter bag drainage device. Data obtained was analyzed with SPSS statistical package (version 16.0). RESULTS: Breast cancer was the malignancy present at diagnosis in 24(58%) patients. Complication rates were similar, 9.5% in the underwater seal group and 10 % in the flutter bag drainage group. The mean duration to full mobilization was 35.0±20.0 hours in the flutter bag group and 52.7±18.5 hours in the underwater seal group, p-value 0.007. The mean length of hospital was 7.9±2.2 days in the flutter bag group and 9.8±2.7 days in the underwater seal group. This was statistically significant, p-value of 0.019. There was no difference in the effectiveness of drainage between both groups, complete lung re-expansion was observed in 16(80%) of the flutter bag group and 18(85.7%) of the underwater seal drainage group, p-value 0.70. CONCLUSION: The flutter valve drainage bag is an effective and safe alternative to the standard underwater seal drainage bottle in the management of non-massive malignant and paramalignant pleural effusion.


Assuntos
Drenagem/métodos , Derrame Pleural Maligno/terapia , Derrame Pleural/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Tubos Torácicos , Drenagem/efeitos adversos , Drenagem/instrumentação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Derrame Pleural/fisiopatologia , Derrame Pleural Maligno/fisiopatologia , Fatores de Tempo , Adulto Jovem
5.
Eur J Cancer Care (Engl) ; 29(2): e13212, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31880035

RESUMO

OBJECTIVE: The incidence and associated healthcare costs of malignant pleural effusion (MPE) are expected to rise, but there is limited evidence about which factors affect patients' prognosis. So, the aim of this study was to determine whether psychological distress at hospital admission is associated with symptom severity and health status in patients with MPE. METHODS: A longitudinal observational prospective cohort study was carried out in the Pulmonology Service of the Granada University Hospital Complex in Granada, Spain. Patients diagnosed with MPE were included and evaluated at hospital admission, at discharge and at one month after discharge. Outcome measures included symptom severity (i.e. dyspnoea, pain and cough) and health status (functionality and self-perceived health status). RESULTS: Significant differences were found in symptoms and the health status, with worse results in the group with psychological distress at discharge. One month after discharge, MPE patients with psychological distress exhibited greater symptoms, including more cough and dyspnoea (p < .05). Moreover, these patients showed worse functionality (p < .05) and self-perceived health status (p < .05). CONCLUSION: Psychological distress is an important factor to take into account in patients with MPE. The presence of psychological distress appears to increase the symptoms and is associated with worse health status after hospitalisation.


Assuntos
Tosse/psicologia , Dispneia/psicologia , Nível de Saúde , Hospitalização , Dor/psicologia , Derrame Pleural Maligno/psicologia , Angústia Psicológica , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/complicações , Tosse/fisiopatologia , Dispneia/fisiopatologia , Feminino , Estado Funcional , Humanos , Tempo de Internação , Estudos Longitudinais , Neoplasias Pulmonares/complicações , Linfoma/complicações , Masculino , Pessoa de Meia-Idade , Dor/fisiopatologia , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/fisiopatologia , Estudos Prospectivos , Índice de Gravidade de Doença , Espanha
6.
Chest ; 157(2): 421-426, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31472154

RESUMO

BACKGROUND: Both elevated pleural elastance (E-PEL) and radiographic evidence of incomplete lung expansion following thoracentesis have been used to exclude patients with a malignant pleural effusion (MPE) from undergoing pleurodesis. This article reports on a cohort of patients with MPE in whom complete drainage was attempted with pleural manometry to determine the frequency of E-PEL and its relation with postthoracentesis radiographic findings. METHODS: Seventy consecutive patients with MPE who underwent therapeutic pleural drainage with pleural manometry were identified. The pressure/volume curves were constructed and analyzed to determine the frequency of E-PEL and the relation of PEL to the postthoracentesis chest radiographic findings. RESULTS: E-PEL and incomplete lung expansion were identified in 36 of 70 (51.4%) and 38 of 70 (54%) patients, respectively. Patients with normal PEL had an OR of 6.3 of having complete lung expansion compared with those with E-PEL (P = .0006). However, 20 of 70 (29%) patients exhibited discordance between postprocedural chest radiographic findings and the pleural manometry results. Among patients who achieved complete lung expansion on the postdrainage chest radiograph, 9 of 32 (28%) had an E-PEL. In addition, PEL was normal in 11 of 38 (34%) patients who had incomplete lung expansion as detected according to the postthoracentesis chest radiograph. CONCLUSIONS: E-PEL and incomplete lung expansion postthoracentesis are frequently observed in patients with MPE. Nearly one-third of the cohort exhibited discordance between the postprocedural chest radiographic findings and pleural manometry results. These findings suggest that a prospective randomized trial should be performed to compare both modalities (chest radiograph and pleural manometry) in predicting pleurodesis outcome.


Assuntos
Elasticidade/fisiologia , Pleura/fisiopatologia , Derrame Pleural Maligno/terapia , Pleurodese , Toracentese , Adulto , Idoso , Cateteres de Demora , Drenagem , Definição da Elegibilidade , Feminino , Humanos , Masculino , Manometria/métodos , Pessoa de Meia-Idade , Pleura/diagnóstico por imagem , Derrame Pleural Maligno/diagnóstico por imagem , Derrame Pleural Maligno/fisiopatologia , Radiografia Torácica , Estudos Retrospectivos
7.
Medicine (Baltimore) ; 98(48): e18251, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31770288

RESUMO

RATIONALE: Small cell carcinoma (SCC) occurs mostly in the lung, and small cell lung cancer accounts for 13% of newly diagnosed lung cancers. Only 2.5% of SCC occurs in extrapulmonary sites, and SCC of pleural origin is especially very uncommon. PATIENT CONCERNS: An 85-year-old man presenting with progressive dyspnea for more than 7 days. DIAGNOSES: Computed tomography scan of the chest showed massive pleural effusion and diffuse nodular thickening of the pleura on the right chest. Sonography-guided needle biopsy of the pleural mass was performed and histologic and immunohistochemical findings revealed SCC. Since no parenchymal lung lesion was observed, the patient was finally diagnosed with SCC of the pleura (SCCP). INTERVENTIONS: Due to the patient's old age and poor performance status, chemotherapy was not performed and only drainage of pleural effusion was conducted for symptom relief. OUTCOMES: Dyspnea improved after pleural effusion drainage. The patient was discharged and transferred to a local medical center for hospice care. LESSONS: Although primary SCCP is extremely rare, SCCP should also be considered as well as mesothelioma in case of presence of a pleural-based mass with massive pleural effusion.


Assuntos
Carcinoma de Células Pequenas , Dispneia , Derrame Pleural Maligno , Neoplasias Pleurais , Toracentese/métodos , Idoso de 80 Anos ou mais , Carcinoma de Células Pequenas/complicações , Carcinoma de Células Pequenas/patologia , Carcinoma de Células Pequenas/fisiopatologia , Dispneia/diagnóstico , Dispneia/etiologia , Cuidados Paliativos na Terminalidade da Vida , Humanos , Biópsia Guiada por Imagem/métodos , Masculino , Pleura/diagnóstico por imagem , Pleura/patologia , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/terapia , Neoplasias Pleurais/complicações , Neoplasias Pleurais/patologia , Neoplasias Pleurais/fisiopatologia , Tomografia Computadorizada por Raios X/métodos , Ultrassonografia de Intervenção/métodos
8.
Medicina (Kaunas) ; 55(9)2019 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-31487930

RESUMO

BACKGROUND AND OBJECTIVES: Plasminogen activator inhibitor-1 (PAI-1) is a fibrinolytic system enzyme whose role in various fibrinolytic processes is currently unknown. In clinical manifestations of pleural liquids of diverse etiology, various levels of fibrinolytic activity can be observed-parapneumonic processes tend to loculate in fibrin septa, while malignant pleural effusion (MPE) does not. The purpose of this study was to determine possible differences in PAI-1 levels in pleural effusions of varied etiology. MATERIAL AND METHODS: PAI-1 level in pleural effusion and serum was determined in 144 patients with pleural effusions of various etiology (cardiac hydrothorax-42 patients (29.2%), MPE-67 patients (46.5%), parapneumonic pleuritis-27 (18.8%), tuberculous pleuritis-6 patients (4.1%), pancreatogenic pleuritis-1 patient (0.7%) and pulmonary artery thromboembolism with pleuritis-1 patient (0.7%)). RESULTS: The median PAI-1 level (ng/mL) was the highest in the parapneumonic pleuritis group both in the effusion and the serum, with values of 291 (213-499) ng/mL and 204 (151-412) ng/mL, respectively, resulting in a statistically significant difference (p < 0.001) from the cardiac hydrothorax and MPE groups. However, there was no statistically significant difference between PAI-1 levels in the pleural effusion and serum in the cardiac hydrothorax and MPE groups. CONCLUSION: The PAI-1 level in MPE and cardiac hydrothorax was statistically significantly lower than in parapneumonic pleuritis.


Assuntos
Hidrotórax/sangue , Inibidor 1 de Ativador de Plasminogênio/análise , Derrame Pleural Maligno/sangue , Pleurisia/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Hidrotórax/fisiopatologia , Letônia , Masculino , Pessoa de Meia-Idade , Inibidor 1 de Ativador de Plasminogênio/sangue , Derrame Pleural Maligno/fisiopatologia , Pleurisia/fisiopatologia
9.
Medicina (Kaunas) ; 55(8)2019 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-31443309

RESUMO

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.


Assuntos
Gerenciamento Clínico , Neoplasias/complicações , Derrame Pleural Maligno/terapia , Feminino , Humanos , Masculino , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/fisiopatologia , Prognóstico
10.
Respirology ; 24(1): 76-82, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-29966171

RESUMO

BACKGROUND AND OBJECTIVE: The main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE. METHODS: Retrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause-specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine-Gray subdistribution hazard model, and externally validated the model. RESULTS: A total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X-ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21-2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43-3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04-1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004-1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43-0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy. CONCLUSION: Pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.


Assuntos
L-Lactato Desidrogenase/análise , Neoplasias , Derrame Pleural Maligno , Toracentese , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias/complicações , Neoplasias/patologia , Cuidados Paliativos/métodos , Derrame Pleural Maligno/metabolismo , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/terapia , Radiografia Torácica/métodos , Recidiva , Estudos Retrospectivos , Medição de Risco/métodos , Fatores de Risco , Toracentese/efeitos adversos , Toracentese/métodos
12.
Ther Adv Respir Dis ; 11(2): 105-114, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27777372

RESUMO

Malignant pleural effusions (MPEs) are an important cause of cancer-related mortality and morbidity. It is a heterogeneous group of conditions, which leads to debilitating symptoms and confers a poor prognosis. Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. Together, with new prognostic scoring systems and a greater understanding of how different patient phenotypes respond to treatment, this allows greater personalization of management. This article will discuss the current evidence on evaluation and management of MPEs.


Assuntos
Derrame Pleural Maligno/terapia , Medicina de Precisão/métodos , Humanos , Fenótipo , Derrame Pleural Maligno/mortalidade , Derrame Pleural Maligno/fisiopatologia , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Projetos de Pesquisa
13.
BMJ Open ; 6(10): e012795, 2016 10 18.
Artigo em Inglês | MEDLINE | ID: mdl-27798020

RESUMO

INTRODUCTION: The development of malignant pleural effusion (MPE) results in disabling breathlessness, pain and reduced physical capability with treatment a palliative strategy. Ambulatory management of MPE has the potential to improve quality of life (QoL). The OPTIMUM trial is designed to determine whether full outpatient management of MPE with an indwelling pleural catheter (IPC) and pleurodesis improves QoL compared with traditional inpatient care with a chest drain and talc pleurodesis. OPTIMUM is currently open for any centres interested in collaborating in this study. METHODS AND ANALYSIS: OPTIMUM is a multicentre non-blinded randomised controlled trial. Patients with a diagnosis of MPE will be identified and screened for eligibility. Consenting participants will be randomised 1:1 either to an outpatient ambulatory pathway using IPCs and talc pleurodesis or standard inpatient treatment with chest drain and talc pleurodesis as per British Thoracic Society guidelines. The primary outcome measure is global health-related QoL at 30 days measured using the EORTC QLQ-C30 questionnaire. Secondary outcome measures include breathlessness and pain measured using a 100 mm Visual Analogue Scale and health-related QoL at 60 and 90 days. A sample size of 142 patients is needed to demonstrate a clinically significant difference of 8 points in global health status at 30 days, for an 80% power and a 5% significance level. ETHICS AND DISSEMINATION: The study has been approved by the NRES Committee South East Coast-Brighton and Sussex (reference 15/LO/1018). The trial results will be published in peer-reviewed journals and presented at scientific conferences. TRIAL REGISTRATION NUMBERS: UKCRN19615 and ISRCTN15503522; Pre-results.


Assuntos
Cateterismo/métodos , Cateteres de Demora , Tubos Torácicos , Drenagem/métodos , Dispneia/terapia , Derrame Pleural Maligno/terapia , Pleurodese/métodos , Idoso , Cateteres de Demora/efeitos adversos , Tubos Torácicos/efeitos adversos , Protocolos Clínicos , Drenagem/instrumentação , Dispneia/etiologia , Dispneia/fisiopatologia , Dispneia/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Derrame Pleural Maligno/complicações , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/psicologia , Qualidade de Vida , Talco/administração & dosagem , Resultado do Tratamento
14.
BMJ Open ; 6(7): e011480, 2016 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-27381209

RESUMO

INTRODUCTION: Malignant pleural effusions (MPEs) can complicate most cancers, causing dyspnoea and impairing quality of life (QoL). Indwelling pleural catheters (IPCs) are a novel management approach allowing ambulatory fluid drainage and are increasingly used as an alternative to pleurodesis. IPC drainage approaches vary greatly between centres. Some advocate aggressive (usually daily) removal of fluid to provide best symptom control and chance of spontaneous pleurodesis. Daily drainages however demand considerably more resources and may increase risks of complications. Others believe that MPE care is palliative and drainage should be performed only when patients become symptomatic (often weekly to monthly). Identifying the best drainage approach will optimise patient care and healthcare resource utilisation. METHODS AND ANALYSIS: A multicentre, open-label randomised trial. Patients with MPE will be randomised 1:1 to daily or symptom-guided drainage regimes after IPC insertion. Patient allocation to groups will be stratified for the cancer type (mesothelioma vs others), performance status (Eastern Cooperative Oncology Group status 0-1 vs ≥2), presence of trapped lung (vs not) and prior pleurodesis (vs not). The primary outcome is the mean daily dyspnoea score, measured by a 100 mm visual analogue scale (VAS) over the first 60 days. Secondary outcomes include benefits on physical activity levels, rate of spontaneous pleurodesis, complications, hospital admission days, healthcare costs and QoL measures. Enrolment of 86 participants will detect a mean difference of VAS score of 14 mm between the treatment arms (5% significance, 90% power) assuming a common between-group SD of 18.9 mm and a 10% lost to follow-up rate. ETHICS AND DISSEMINATION: The Sir Charles Gairdner Group Human Research Ethics Committee has approved the study (number 2015-043). Results will be published in peer-reviewed journals and presented at scientific meetings. TRIAL REGISTRATION NUMBER: ACTRN12615000963527; Pre-results.


Assuntos
Cateteres de Demora , Drenagem , Dispneia/terapia , Neoplasias Pulmonares/prevenção & controle , Mesotelioma/prevenção & controle , Derrame Pleural Maligno/terapia , Pleurodese , Adulto , Idoso , Austrália/epidemiologia , Líquidos Corporais , Protocolos Clínicos , Drenagem/métodos , Dispneia/fisiopatologia , Feminino , Hong Kong/epidemiologia , Humanos , Neoplasias Pulmonares/epidemiologia , Masculino , Mesotelioma/epidemiologia , Mesotelioma Maligno , Nova Zelândia/epidemiologia , Derrame Pleural Maligno/epidemiologia , Derrame Pleural Maligno/fisiopatologia , Pleurodese/métodos , Estudos Prospectivos , Qualidade de Vida , Talco , Resultado do Tratamento
15.
Eur Respir Rev ; 25(140): 189-98, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27246596

RESUMO

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.


Assuntos
Derrame Pleural Maligno , Animais , Biomarcadores/metabolismo , Ensaios de Triagem em Larga Escala , Humanos , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/mortalidade , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/terapia , Valor Preditivo dos Testes , Prognóstico , Fatores de Risco , Toracoscopia
16.
Endocr J ; 63(3): 257-61, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26655349

RESUMO

Metastatic differentiated thyroid carcinoma (DTC) is an uncommon cause of malignant pleural effusion (MPE) and the characteristics and clinical course have been rarely described. Herein, we report a retrospective review of the clinical course of 18 patients (15 women and 3 men) with MPE from DTC who underwent treatment at our institution between January 2005 and December 2014. MPE from DTC was diagnosed based on cytology and/or level of thyroglobulin in the pleural fluid. Pathologically, papillary carcinoma was found in 16 patients and follicular carcinoma in 2 patients. Median ages at initial diagnosis of DTC and MPE were 64 years (range, 22-79) and 74 years (range, 39-86), respectively. All patients showed radiologically apparent lung metastases, with MPE developing after 0-212 months (median, 25). In 16 patients (88.9%), other coexistent distant metastases at the time of MPE diagnosis were found in the bone (n = 10), brain (n = 5), and skin (n = 2). All patients were treated conservatively with palliative thoracentesis or chest tube drainage with or without pleurodesis. Recurrent MPE after treatment was seen in 9 patients; discharge to home health care after treatment for MPE was possible for 14 patients. The overall survival after initial diagnosis varied considerably from 14 months to 37 years, but the median survival after appearance of MPE was 10 months (range, 1-28). Systemic therapy for iodine-resistant recurrent thyroid disease may need to be considered as a treatment option for patients with MPE.


Assuntos
Adenocarcinoma Folicular/fisiopatologia , Carcinoma Papilar/fisiopatologia , Neoplasias Pulmonares/secundário , Derrame Pleural Maligno/etiologia , Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/fisiopatologia , Adenocarcinoma Folicular/patologia , Adenocarcinoma Folicular/secundário , Adenocarcinoma Folicular/cirurgia , Adulto , Idoso , Carcinoma/patologia , Carcinoma/fisiopatologia , Carcinoma/cirurgia , Carcinoma Papilar/patologia , Carcinoma Papilar/secundário , Carcinoma Papilar/cirurgia , Feminino , Hospitais Urbanos , Humanos , Japão , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/fisiopatologia , Neoplasias Pulmonares/terapia , Excisão de Linfonodo/efeitos adversos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Cuidados Paliativos , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/fisiopatologia , Derrame Pleural Maligno/terapia , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Câncer Papilífero da Tireoide , Glândula Tireoide/cirurgia , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia/efeitos adversos , Adulto Jovem
17.
Southeast Asian J Trop Med Public Health ; 46(3): 496-503, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-26521524

RESUMO

Tuberculous and malignant pleural effusions share similar clinical and radiographic findings and both may produce lymphocytic-predominant exudative effusions. This study aimed to determine distinguishing clinical features between the two diseases. We conducted a retrospective study among 47 patients with tuberculous pleural effusions (TBPE) and 73 with malignant pleural effusions (MPE). Demographic data, clinical features, pleural fluid characteristics, and radiographic findings were obtained for each patient and the 2 groups were compared. Sixty-nine (57.5%) patients were males. The mean (+/- SD, range) age was 60.2 (+/- 16.9, 19-94) years. Mean (+/- SD) symptom duration was 31.6 (+/- 51.6) days. Univariate analysis identified 20 clinical, pleural fluid and radiological differences between the two groups. Multivariate logistic regression analysis revealed 3 independent predictors of TBPE: fever (OR=8.2; 95% CI: 1.9 - 35.9; p=0.005), having a non-serosanguinous effusion (OR=6.1; 95% CI: 1.1 - 33.6; p=0.038), and a fluid adenosine deaminase level > 30 U/I (OR=86.7; 95% CI: 4.3 - 1735; p=0.004). Fever, non-serosanguinous pleural effusions and high adenosine deaminase levels were suggestive of a TBPE and could be clinically useful when evaluating a pleural effusion of unknown etiology.


Assuntos
Dor no Peito/etiologia , Dispneia/etiologia , Febre/etiologia , Neoplasias/complicações , Derrame Pleural Maligno/etiologia , Derrame Pleural/etiologia , Tuberculose Pulmonar/complicações , Adenosina Desaminase/análise , Adulto , Idoso , Neoplasias da Mama/complicações , Exsudatos e Transudatos/química , Exsudatos e Transudatos/citologia , Feminino , Humanos , Modelos Logísticos , Neoplasias Pulmonares/complicações , Linfoma/complicações , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Derrame Pleural/diagnóstico por imagem , Derrame Pleural/fisiopatologia , Derrame Pleural Maligno/diagnóstico por imagem , Derrame Pleural Maligno/fisiopatologia , Radiografia , Estudos Retrospectivos
18.
Clin J Oncol Nurs ; 19(5): 501-4, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26414568

RESUMO

Malignant pleural effusions (MPEs) are common complications that occur with advanced stages of cancer. In general, they indicate a poor prognosis and greatly affect quality of life (QOL). The treatment goal of MPEs is to provide relief of symptoms. The standard treatment for MPEs is talc pleurodesis; however, indwelling pleural catheters have become more frequently used. This article focuses on current management strategies for MPEs and assesses their influence on QOL.At a GlanceSymptoms of malignant pleural effusions (MPEs), which involve the accumulation of fluid in the pleural space, include dyspnea, shortness of breath, chest pain, and other issues that decrease functional status.Treatment for MPEs should be palliative, achieving immediate symptom relief and improved quality of life.The optimal treatment strategy for MPEs should have minimal side effects, require minimal or no hospitalization, and have low rates of recurrence.


Assuntos
Derrame Pleural Maligno/tratamento farmacológico , Pleurodese , Cateteres de Demora , Humanos , Cuidados Paliativos , Derrame Pleural Maligno/fisiopatologia , Talco/uso terapêutico
19.
PLoS One ; 10(4): e0123798, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25874452

RESUMO

BACKGROUND: The minimal important difference (MID) is essential for interpreting the results of randomised controlled trials (RCTs). Despite a number of RCTs in patients with malignant pleural effusions (MPEs) which use the visual analogue scale for dyspnea (VASD) as an outcome measure, the MID has not been established. METHODS: Patients with suspected MPE undergoing a pleural procedure recorded their baseline VASD and their post-procedure VASD (24 hours after the pleural drainage), and in parallel assessed their breathlessness on a 7 point Likert scale. FINDINGS: The mean decrease in VASD in patients with a MPE reporting a 'small but just worthwhile decrease' in their dyspnea (i.e. equivalent to the MID) was 19mm (95% CI 14-24mm). The mean drainage volume required to produce a change in VASD of 19mm was 760ml. INTERPRETATION: The mean MID for the VASD in patients with a MPE undergoing a pleural procedure is 19mm (95% CI 14-24mm). Thus choosing an improvement of 19mm in the VASD would be justifiable in the design and analysis of future MPE studies.


Assuntos
Neoplasias da Mama/cirurgia , Carcinoma Pulmonar de Células não Pequenas/cirurgia , Dispneia/diagnóstico , Dispneia/cirurgia , Mesotelioma/cirurgia , Neoplasias Ovarianas/cirurgia , Derrame Pleural Maligno/cirurgia , Idoso , Neoplasias da Mama/complicações , Neoplasias da Mama/fisiopatologia , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma Pulmonar de Células não Pequenas/fisiopatologia , Drenagem/métodos , Dispneia/complicações , Dispneia/fisiopatologia , Feminino , Humanos , Masculino , Mesotelioma/complicações , Mesotelioma/fisiopatologia , Pessoa de Meia-Idade , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/fisiopatologia , Derrame Pleural Maligno/complicações , Derrame Pleural Maligno/fisiopatologia , Índice de Gravidade de Doença , Inquéritos e Questionários , Escala Visual Analógica
20.
Cell Biochem Biophys ; 71(3): 1325-33, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25413961

RESUMO

The aim of the study was to investigate the mechanism of arsenic trioxide (As2O3) in the treatment of malignant pleural effusion (MPE) caused by pleural metastasis of lung cancer. A mouse model of MPE caused by pleural metastasis of lung cancer was first established, and As2O3 was then intraperitoneally injected to treat the MPE. Mice treated with bevacizumab and bleomycin were included as positive controls, and placebo equivalents were also used as negative controls. The effects of As2O3 on MPE volume, pleural vessel density, vascular permeability, expression of angiogenic function-related factors, including vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α), as well as nuclear factor-κB (NF-κB) activity in pleural carcinomatosis, were observed. Intraperitoneal injection of As2O3 reduced the volume of MPE and decreased vascular density and permeability in pleural metastatic nodules in a dose-dependent manner. Moreover, dose-dependent decreases in VEGF and TNF-α expression in MPE, and NF-κB activity in pleural carcinomatosis, were also found after As2O3 treatment. We showed that As2O3 can down-regulate VEGF expression via inhibition of NF-κB, and decrease vascular density and permeability in pleural metastatic nodules, thereby eliciting its effects on MPE caused by pleural metastasis of lung cancer. Our results provide a foundation for an As2O3-based clinical treatment program.


Assuntos
Arsenicais/farmacologia , Neoplasias Pulmonares/patologia , Óxidos/farmacologia , Derrame Pleural Maligno/tratamento farmacológico , Animais , Trióxido de Arsênio , Arsenicais/uso terapêutico , Linhagem Celular Tumoral , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Microvasos/efeitos dos fármacos , Microvasos/metabolismo , NF-kappa B/metabolismo , Metástase Neoplásica , Óxidos/uso terapêutico , Permeabilidade/efeitos dos fármacos , Derrame Pleural Maligno/metabolismo , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/fisiopatologia , Carga Tumoral/efeitos dos fármacos , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...